Plasma Gelsolin

Plasma gelsolin (pGSN) is an 83 kDa abundant protein constituent of normal plasma and an important component of the innate immune system. The identification of pGSN in ''Drosophila melanogaster'' and ''C. elegans'' points to an ancient origin early in evolution. Its extraordinary structural conservation reflects its critical regulatory role in multiple essential functions. Its roles include the breakdown of filamentous actin released from dead cells, activation of macrophages, and localization of the inflammatory response. Substantial decreases in plasma levels are observed in acute and chronic infection and injury in both animal models and in humans. Supplementation therapies with recombinant human pGSN have been shown effective in more than 20 animal models.

pGSN has a cytoplasmic isoform (cGSN) known to be an actin-binding protein controlling cytoskeletal dynamics. cGSN is expressed from the same gene, and is identical to pGSN except for its lack of a 24 amino acid N-terminal extension.

History

The cellular isoform of Gelsolin was discovered in 1979 in the lab of Thomas P. Stossel. Its name comes from observed calcium-dependent reversible ''gel-sol'' transitions of macrophage cytoplasmic extract. Around the same time a similarly sized plasma protein was discovered and shown to depolymerize actin; it was named Brevin, due to its ability to shorten actin filaments.
In 1986 it was demonstrated that Brevin was identical to cellular Gelsolin except for a 24 AA N-terminal extension, and was renamed Plasma Gelsolin.

Structure

Plasma Gelsolin is a 755 AA, 83 kDa plasma protein made up of six "gelsolin domains," each composed of a 5-6 strand β-sheet between one long and one short α-helix.
It exhibits a weak homology between domains S1 and S4, S2 and S5, and S3 and S6, and is identical to the cytoplasmic form of the protein except for the addition of a 24 AA N-terminal extension. Additionally a 27 AA N-terminal signal peptide is cleaved prior to pGSN's secretion from the cell. Both forms of the protein are encoded by highly conserved genes on chromosome 9 in humans, but are under the control of different promoters.
There is a single disulfide bond formed on the second domain of the plasma protein, there are no documented natural post-translational modifications, and the pI ≈ 6.

Isoforms and mutations

Aside from the cellular form, the only other known isoform is Gelsolin-3, an identical non-secreted protein containing an 11 AA, rather than 24 AA, N-terminal extension. It has been found in brain, testes, and lung oligodendrocytes, and is reportedly involved in myelin remodeling during spiralization around the axon.

Plasma Gelsolin is highly conserved, and its only known mutations are single point mutations.
One of several such mutations leads to Finnish Familial Amyloidosis, a disorder in which pGSN becomes more conformationally flexible and susceptible to enzymatic cleavage resulting in accumulation of peptide fragments into amyloid fibrils.
D187N/Y is the most common mutation with additional reports of G167R, N184K, P432R, A551P, and Ala7fs in the medical literature.
In addition to this several mutations as well as down-regulation of the protein are associated with breast cancer.

Ca²⁺

At moderate pH in the absence of Ca²⁺ pGSN is compact and globular. Low pH or the presence of >nM Ca²⁺ is associated with an elongated structure with greater backbone flexibility.
This flexibility exposes the actin binding sites.
Since physiological levels of Ca²⁺ are ~2 mM, pGSN is natively elongated and able to bind to leaked actin from cellular damage.

Functions

Binding

Plasma Gelsolin is a sticky protein known to bind to a number of peptides and proteins:
Actin (see: Relationships with actin),
Apo-H,
Aβ,
α-Synuclein,
Integrin,
Tcp-1,
Fibronectin,
Syntaxin-4,
Tropomyosin,
fatty acids and phospholipids (see: Binding and inactivation of diverse inflammatory mediators): LPA,
LPS (endotoxin),
LTA,
PAF,
S1P,
polyphosphoinositides including PIP₂;
and nucleic acids: Ap3A,
ATP,
ADP.
PIP₂, a phospholipid component of cell membranes, competes with ATP and actin for pGSN binding, and will dissociate F-Actin-capped pGSN.

Relationships with actin

Actin toxicity and removal

Actin is the most abundant cellular protein, and its release into extracellular fluid and circulation following cellular injury from disease or injury leads to increased blood viscosity, hindered microcirculation, and activation of platelets. Hemodialysis patients with low levels of pGSN and high levels of actin in blood had markedly higher mortality. Actin is a major component of biofilms that accumulate at local sites of injury and infection, impeding access of host immune components and therapeutics such as antibiotics.
Biofilms are particularly pathogenic in the setting of foreign bodies like indwelling catheters and tissue implants.

Actin exchanges between monomeric (G) and filamentous (F) forms according to the concentrations of it, ATP, and cations.
pGSN along with Vitamin D-binding protein (DBP) bind and clear monomeric actin. DBP binds with greater affinity to G-actin, leaving pGSN available to sever F-actin. Furthermore, DBP is capable of removing one actin from a 2:1 actin-pGSN complex, restoring its ability to sever F-actin.
F-actin, severed and capped by pGSN, is removed by sinusoidal endothelial cells of the liver. pGSN removes 60% of actin trapped in fibrin clots ''in vitro'' leading to an increased rate of clot lysis.

Severing, capping, nucleation, and polymerization

Although pGSN is capable of initiating the polymerization of actin through nucleation, its primary relationship with it in blood is depolymerization through filament severing. Actin severing occurs rapidly in the presence of pGSN and Ca²⁺.
pGSN wraps around filaments, non-enzymatically cleaving them.
It remains attached, "capping" the barbed/plus end of the severed filament and inducing a torsional twist that is cooperative through its length. Capping has a reported binding affinity <250 pM in the presence of Ca²⁺ that is substantially weakened in its absence. Capping also blocks further polymerization at the fast growing, barbed end.

While no evidence exists for nucleating/polymerizing of G-actin by pGSN ''in vivo'', the ability of it to do so ''in vitro'' is well documented.
Actin polymerization is initiated by the production of an actin trimer nucleus.
Formation of nuclei is energetically disfavored, but dimers and/or trimers can be catalyzed/stabilized by a number of cellular proteins.
In excess of a 2:1 actin:gelsolin stoichiometry and in the presence of Ca²⁺, gelsolin will bind three actin monomers.
A monomer adds to the trimer creating a tetramer that undergoes an internal conversion to an active tetramer witnessed by a concentration-independent lag phase. Subsequent fibrilization proceeds by monomer addition.
Gelsolin remains attached to the fast-growing (barbed/plus) end of actin, producing short, slow-growing fibrils.

These actions are similar to those of cytoplasmic form of pGSN, cGSN, which contributes to structural changes of cells through both nucleating/polymerizing and severing/capping.

Amyloid prevention and clearance

pGSN may play an important role in the prevention and management of amyloidosis in several diseases. It is found in complex with Aβ in plasma and reported to both inhibit amyloid formation and defibrillize preformed fibrils ''in vitro''. Mice with an Alzheimer's disease model given pGSN showed a 5-fold decrease in progression of Cerebral Amyloid Angiopathy. pGSN has also been found in Lewy Bodies, amyloid containing protein aggregates associated with Parkinson's disease and Dementia with Lewy bodies.

Role in inflammation

Macrophage stimulation

MARCO receptor

Macrophage receptor MARCO is responsible for pathogen recognition and phagocytosis. Macrophages incubated with actin at concentrations consistent with lung injury showed decreased uptake of bacteria. Uptake was restored when actin was administered in the presence of pGSN.

NOS3

NOS3 is an enzyme that is protective against systemic inflammation and myocardial dysfunction.
pGSN activates phosphorylation of Ser¹¹⁷⁷ in NOS3 and Ser⁴⁷³ in Akt.
NOS3 is known to be activated by phosphorylation of Akt.
Mouse macrophage uptake and killing of bacteria ''in vitro'' was enhanced by pGSN, and no significant enhancement was found for NOS3^-/- macrophages.
''In vivo'', mice showed 15-fold improvement in bacterial clearance when given pGSN, and no significant enhancement was found for NOS3^-/- mice.

Inflammatory mediators

pGSN has been shown to bind to the fatty acid inflammatory mediators LPA,
LPS (endotoxin),
LTA,
PAF,
S1P,
and polyphosphoinositides including PIP₂. Mediators of inflammation, the body's innate healing mechanism, accumulate at the site of the injury to begin the processes of defense and repair, and the depletion of local pGSN allows them to do their work.

See Binding and inactivation of diverse inflammatory mediators

Therapeutic potential

The broad therapeutic potential of pGSN supplementation resides in the fact that the molecule embodies a multifunctional system contributing importantly to innate immunity rather than a pharmacologic intervention with selective and specific activities.

Plasma gelsolin's primary function is to keep inflammation local and enhance the function of the innate immune system. It functions through a pleiotropic mechanism of action; severing toxic filamentous actin (F-actin), binding inflammatory mediators, and enhancing pathogen clearance. These mechanisms are quite distinct from other anti-inflammatory agents that function as antagonists

HOME


Content is Copyleft
Website design, code, and AI is Copyrighted (c) 2014-2017 by Stephen Payne


Consider donating to Wikimedia



As an Amazon Associate I earn from qualifying purchases